What is RMD stock price target for 2026?

WallStSmart's 12-month price target for ResMed Inc is $228.51, representing 7.8% upside from the current price of $211.93.

What is RMD stock forecast?

ResMed Inc forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is RMD undervalued based on price targets?

Our DCF intrinsic value for ResMed Inc is $223.24, against a current price of $211.93. The margin of safety is -16.30%.

RMD

ResMed Inc

NYSE: RMD · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$211.93

-2.40% today

Updated 2026-04-29

Market cap

$30.87B

P/E ratio

20.96

P/S ratio

5.72x

EPS (TTM)

$10.11

Dividend yield

1.04%

52W range

$212 – $292

Volume

1.0M

Market cap

$30.87B

P/E ratio

20.96

P/S ratio

5.72x

EPS (TTM)

$10.11

Dividend yield

1.04%

52W range

$212 – $292

Volume

1.0M

ResMed Inc (RMD) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$211.93

Consensus

$293.70

+38.58%

2030 Target

$627.45

+196.06%

DCF

$223.24

-16.30% MoS

Current price

$211.93

Analyst consensus

$293.70

+38.58%

2030 Target

$627.45

+196.06%

Intrinsic (DCF)

$223.24

-16.30% MoS

10 analysts:

5 Buy4 Hold1 Sell

Management guidance

No specific CEO revenue targets disclosed in available data. Management has guided to 10.58% revenue growth for FY2026 ($5.69B) and 7.38% growth for FY2027 ($6.11B) based on analyst consensus. Company maintains strong organic growth trajectory with digital health expansion and international market opportunities.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$1,030.81

$7.5B Rev × 20x P/S

Base case (2030)

$627.45

$7.5B Rev × 12x P/S

Bear case (2030)

$403.36

$7.5B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$4.2B	$4.7B	$5.1B	$5.7B	$6.1B	$6.6B	$7.0B	$7.5B
Revenue growth	—	10.9%	9.8%	10.6%	7.4%	7.3%	7.0%	6.8%
EPS	—	$7.73	$5.36	$11.12	$12.28	$13.50	$14.75	$16.10
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$470.59	$493.00	$537.82	$582.63	$627.45

Catalysts & risks

Growth catalysts

+ Digital health and cloud-based software expansion driving recurring revenue

+ International market penetration offsetting U.S. sleep apnea demand normalization

+ Innovation in mask technology and respiratory care devices

+ Aging population and chronic disease prevalence supporting long-term demand

Key risks

- GLP-1 weight-loss drug adoption reducing obesity-related sleep apnea cases

- Insurance reimbursement pressure and competitive intensity

- U.S. CPAP device market saturation and slowing demand growth

- Execution risk on digital health strategy and international expansion

Methodology

ResMed Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 10 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.